Radt-43. Development and Validation of a Prognostic Nomogram for Diffuse Midline Glioma: a Population-based Study
Year: 2025
Type: conference-abstract
Abstract: Diffuse midline glioma (DMG), defined by loss of histone H3 lysine-27 trimethylation (H3K27me3), remains a universally fatal pediatric CNS malignancy with limited therapeutic options. We constructed the largest-to-date prognostic nomogram (n=409) using SEER-22 data (2018–2021), integrating age, tumor location, treatment modality, and socioeconomic status. Our analysis revealed an age-dependent anatomical distribution: brainstem tumors were predominant in children, while adults more commonly presented with non-brainstem disease. Combined chemoradiotherapy (CRT) significantly improved survival (HR=0.41, 95% CI: 0.27–0.63), while chemotherapy alone conferred no benefit. Surgical resection had no impact on survival, consistent with the infiltrative nature of DMG. The nomogram demonstrated moderate discriminative performance (C-index=0.66) and effectively stratified patients into high- and low-risk groups. This model provides a clinically actionable framework for DMG management, supporting risk-adapted strategies: intensified or novel therapies for high-risk patients, and standard CRT for low-risk groups.
Source: Neuro-Oncology
Authors: Ge Zhang, Xiaoying Xue*
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4416141470
Cites:
Cited by:
Related to: